Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FMED9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $199,010
Award facts
- Contract value 100% obligated
- $199,009.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $199,009.56 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The delivery order, issued on January 5, 2026, with an ultimate completion date of January 27, 2026, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense healthcare facilities worldwide. The parent IDC, designated SPE2DR and valued at $499,999,999, was awarded in November 2025 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional prime vendor contractor.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a pharmaceutical supplier to the Defense Logistics Agency's Medical Supply Chain division, with a product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The contractor's selection reflects its competitive capability and established performance in supplying specialized pharmaceutical products to support military medical operations. Stelara, an immunosuppressant biologic agent used in the treatment of autoimmune conditions, represents one of many specialized pharmaceutical products the contractor supplies under the PPV-G GEN V contract structure, which enables rapid delivery order issuance to meet the recurring medical supply needs of the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FMED9?
SPE2DR26FMED9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FMED9 worth?
The government has obligated $199,010 on SPE2DR26FMED9.
Is contract SPE2DR26FMED9 an order under another contract?
Yes. SPE2DR26FMED9 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMED9 competed?
The extent of competition for SPE2DR26FMED9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award